VCEL - ヴェリセル （Vericel Corporation） ヴェリセルVCELのチャート
VCELの企業情報
| symbol | VCEL |
|---|---|
| 会社名 | Vericel Corp （ヴェリセル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ヴェリセル（Vericel Corporation）（旧名：Aastrom Biosciences Inc.）は正常組織及び機能を回復させるために損傷した組織および器官を修復・再生させる治療法の特定・開発・商品化に従事する商業段階のバイオ医薬品会社である。同社は特定の疾患の治療に使用するための患者特異的な拡大された細胞療法の研究・開発・製造・流通を通じて事業を行う。自己細胞治療製品には、膝の軟骨欠損の治療のための自己軟骨細胞インプラントであるCarticel（自己培養軟骨細胞）、及び深層皮膚または全層熱傷患者の治療のための恒久的な皮膚代替物であるEpicel（培養表皮自家移植片）が含まれる。同社は第三世代自己軟骨細胞インプラントであるMACI、及び患者特異的多細胞療法であるixmyelocel-Tを開発している。 ヴェリセルは米国のバイオ医薬品会社で、自己細胞療法の開発と商品化に焦点を置く。膝軟骨欠損治療用の培養細胞移植片「カ―ティセル」、重度やけど用の自己皮膚移植片「エピセル」、軟骨細胞移植片「MACT」を製造、販売。また、拡張型心筋症による進行性心不全治療の多細胞療法の治験を行う。 about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea |
| 本社所在地 | 64 Sidney Street Cambridge MA 02139 USA |
| 代表者氏名 | Robert L. Zerbe ロバート・L・ゼルベ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 734-930-5555 |
| 設立年月日 | 32568 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 205人 |
| url | www.vcel.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vcel |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.75300 |
| 終値（lastsale） | 13.5 |
| 時価総額（marketcap） | 576807142.5 |
| 時価総額 | 時価総額（百万ドル） 542.62600 |
| 売上高 | 売上高（百万ドル） 74.64800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 464.92100 |
| 当期純利益 | 当期純利益（百万ドル） -17.43000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Vericel Corp revenues increased 41% to $37M. Net loss increased 1% to $12.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Selling General Expense increase of 25% to $20.4M (expense) (Increase) decrease in fair value of war decrease from $548K (income) to $2.9M (expense). |
VCELのテクニカル分析
VCELのニュース
Vericel Corporation (VCEL) Q1 2023 Earnings Call Transcript 2023/05/10 15:34:08 Seeking Alpha
Vericel Corporation (NASDAQ:NASDAQ:VCEL) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ETCompany ParticipantsEric Burns - Vice President, Finance and Investor RelationsNick…
Vericel Corporation 2023 Q1 - Results - Earnings Call Presentation 2023/05/10 14:04:16 Seeking Alpha
The following slide deck was published by Vericel Corporation in conjunction with their 2023 Q1 earnings call.
Regenerative Medicine Market Report Size, Research Analysis, Share, Industry Growth, Opportunities, Business Expansion, Forecast to 2027 2023/05/10 13:00:00 SBWire
In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function. Northbrook, IL 60062 -- ( SBWIRE ) -- 05/10/2023 -- The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579 Regenerative Medicine Industry Dynamics Drivers: Availability of funding and rising investments in R&D The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities.
Vericel: Q1 Earnings Insights 2023/05/10 12:16:28 Benzinga
Vericel (NASDAQ: VCEL ) reported its Q1 earnings results on Wednesday, May 10, 2023 at 07:55 AM. Here''s what investors need to know about the announcement. Earnings Vericel missed estimated earnings by 6.67%, reporting an EPS of $-0.16 versus an … Full story available on Benzinga.com
Vericel GAAP EPS of -$0.16 misses by $0.01, revenue of $41.01M beats by $3.64M 2023/05/10 11:57:23 Seeking Alpha
Vericel press release (VCEL): Q1 GAAP EPS of -$0.16 misses by $0.01.Revenue of $41.01M (+13.7% Y/Y) beats by $3.64M.Full-Year 2023 Revenue Guidance Raised to $184-$192…
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023 2023/04/26 12:30:00 GlobeNewswire
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel Corporation: A Promising Future In Advanced Cell Therapies (VCEL) 2023/04/02 13:14:27 Seeking Alpha
Vericel Corporation is an innovative leader with a strong pipeline of FDA-approved and investigational products that address unmet medical needs. Click here to read more.
Can you still get a good price for Vericel Corporation (VCEL) Shares at this point? 2023/03/10 15:48:00 US Post News
A share of Vericel Corporation (NASDAQ:VCEL) closed at $29.61 per share on Thursday, down from $30.48 day before. While Vericel Corporation has underperformed by -2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -19.03%, with highs and lows ranging from $41.24 to $17.30, […]
Vericel Corporation PT Raised to $31 at Truist Securities 2023/02/27 12:22:03 Investing.com
https://www.investing.com/news/pro/vericel-corporation-pt-raised-to-31-at-truist-securities-432SI-3015443
Vericel Corporation (VCEL) did well last session? 2023/02/24 15:24:00 US Post News
The share price of Vericel Corporation (NASDAQ:VCEL) rose to $30.60 per share on Thursday from $28.52. While Vericel Corporation has overperformed by 7.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -8.05%, with highs and lows ranging from $43.97 to $17.30, whereas the […]
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023 2023/04/26 12:30:00 GlobeNewswire
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel Corporation: A Promising Future In Advanced Cell Therapies (VCEL) 2023/04/02 13:14:27 Seeking Alpha
Vericel Corporation is an innovative leader with a strong pipeline of FDA-approved and investigational products that address unmet medical needs. Click here to read more.
Can you still get a good price for Vericel Corporation (VCEL) Shares at this point? 2023/03/10 15:48:00 US Post News
A share of Vericel Corporation (NASDAQ:VCEL) closed at $29.61 per share on Thursday, down from $30.48 day before. While Vericel Corporation has underperformed by -2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -19.03%, with highs and lows ranging from $41.24 to $17.30, […]
Vericel Corporation PT Raised to $31 at Truist Securities 2023/02/27 12:22:03 Investing.com
https://www.investing.com/news/pro/vericel-corporation-pt-raised-to-31-at-truist-securities-432SI-3015443
Vericel Corporation (VCEL) did well last session? 2023/02/24 15:24:00 US Post News
The share price of Vericel Corporation (NASDAQ:VCEL) rose to $30.60 per share on Thursday from $28.52. While Vericel Corporation has overperformed by 7.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -8.05%, with highs and lows ranging from $43.97 to $17.30, whereas the […]